诺思格(301333)：Q3收入稳健增长 利润增速超预期

Core Viewpoint - The company reported steady revenue growth and exceeded profit expectations in Q3 2025, driven by a low base from the previous year and a higher number of project settlements [1][2][3]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 607 million, a year-on-year increase of 8.09%, and a net profit attributable to shareholders of 96 million, up 13.21%. The net profit after deducting non-recurring items was 81 million, reflecting a growth of 22.47% [1]. - In Q3 2025 alone, the company recorded revenue of 228 million, representing a year-on-year growth of 24.48%. The net profit attributable to shareholders was 34 million, up 32.98%, while the net profit after deducting non-recurring items reached 30 million, marking a significant increase of 52.69% [2]. - The gross profit margin for the first three quarters was 35.61%, down 3.58 percentage points year-on-year, while the net profit margin increased by 0.65 percentage points to 15.94%. Management and sales expense ratios improved, with management expenses at 10.07% (down 5.11 percentage points) and sales expenses at 1.66% (down 0.24 percentage points) [2]. Industry Outlook - The onset of a rate-cutting cycle by the Federal Reserve, with a 25 basis point cut in September 2025 and expectations for further cuts, is anticipated to gradually revive investment and financing, benefiting the clinical CRO sector [3]. - The introduction of domestic innovative drug support policies is expected to favor local clinical CROs, positioning the company for rapid growth opportunities [3]. Profit Forecast and Investment Recommendation - Revenue projections for 2025-2027 are estimated at 776 million, 852 million, and 969 million, with year-on-year growth rates of 4.33%, 9.75%, and 13.79%, respectively. Net profit attributable to shareholders is forecasted at 150 million, 163 million, and 181 million, with growth rates of 6.85%, 8.83%, and 11.26% [3]. - The company is assigned a "buy" rating with corresponding price-to-earnings ratios of 33, 31, and 28 for the years 2025, 2026, and 2027 [3].